Direct Comparison of Transcardiac Increase in Brain Natriuretic Peptide (BNP) and N-Terminal ProBNP and Prognosis in Patients With Chronic Heart Failure

Tsutamoto, Takayoshi; Sakai, Hiroshi; Nishiyama, Keizo; Tanaka, Toshinari; Fujii, Masazumi; Yamamoto, Takashi; Horie, Minoru

doi:10.1253/circj.71.1873

Cited by 33 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Plasma concentrations of NT-proBNP were measured using an automated Elecsys proBNP sandwich immunoassay (Roche Diagnostics) as previously reported. 23 Plasma NE concentrations were measured by high-performance liquid chromatography as reported previously. 22 …”

Section: Measurement Of Ne Bnp and Nt-probnp Concentrationsmentioning

confidence: 99%

Dose-Dependent Prognostic Effect of Carvedilol in Patients With Chronic Heart Failure Special Reference to Ranscardiac Gradient of Norepinephrine

Nishiyama

Tsutamoto

Yamaji

et al. 2009

Circ J

Self Cite

View full text Add to dashboard Cite

Background:The effect of the dose of carvedilol on cardiac sympathetic nerve activity (CSA) and mortality remain uncertain in patients with chronic heart failure (CHF). Methods and Results:To compare the dose of carvedilol and the transcardiac gradient of norepinephrine (NE), a biomarker of CSA, and prognosis in patients with CHF, hemodynamic parameters and plasma levels of NE, N-terminal brain natriuretic peptide (NT-proBNP) in the aortic root and coronary sinus were measured in 107 patients with systolic CHF who received carvedilol. Patients were divided into 2 groups [group I: low dose (<10 mg/day, n=41) and group II: high dose (≥10 mg/day, n=66)]. There was no difference between the 2 groups for the hemodynamic parameters. The dose of carvedilol did not correlate with plasma NE, but was significantly correlated with the transcardiac increase in NE. During a median follow-up of 4.3 years, 13 patients died of cardiac disease. In the Cox stepwise multivariate analyses, a high level of transcardiac increase in NE (P<0.001), high level of plasma log NT-proBNP (P=0.004) and low dose of carvedilol (P=0.012) were significant independent predictors. Conclusion:The carvedilol dose is important for the management of CSA and prognosis in patients with systolic CHF. (Circ J 2009; 73: 2270 -2275

show abstract

Section: Measurement Of Ne Bnp and Nt-probnp Concentrationsmentioning

confidence: 99%

Dose-Dependent Prognostic Effect of Carvedilol in Patients With Chronic Heart Failure Special Reference to Ranscardiac Gradient of Norepinephrine

Nishiyama

Tsutamoto

Yamaji

et al. 2009

Circ J

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Several clinical studies have demonstrated that plasma levels of BNP and NT-proBNP are useful biomarkers to evaluate the severity and the prognosis of patients with heart failure. [5][6][7] Evaluation of the left ventricular filling pressure or pulmonary capillary wedge pressure is important, especially in patients with severe heart failure, however, direct hemodynamic measurements by Swan-Ganz catheters have not been regularly performed [8][9][10][11] and it has been often estimated by the plasma levels of ANP, BNP, and NT-proBNP and these peptides demonstrate almost equal values under various treatments for heart failure. [12][13][14][15][16] Because two endogenous natriuretic peptides, ANP and BNP, bind to natriuretic peptide receptors (NPR); NPR-A and NRP-C receptors with a relatively higher selectivity for ANP than BNP, 17,18) plasma levels of BNP may be affected by carperitide (ANP) infusion.…”

mentioning

confidence: 99%

Plasma NT-proBNP as a More Reliable Biomarker of Endogenous Cardiac Natriuretic Peptides Than BNP During Carperitide Infusion

et al. 2009

Self Cite

View full text Add to dashboard Cite

SummaryBecause both atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) competitively bind to natriuretic peptide receptors but not N-terminal proBNP (NT-proB-NP), the diagnostic value of BNP as a marker of the severity of heart failure in comparison with NT-proBNP during exogenous ANP (carperitide) infusion remains unclear.Forty-two patients with CHF (NYHA class III or IV) treated with the infusion of carperitide were included in the present study. We measured plasma levels of BNP and NT-proBNP at baseline and after the improvement of symptoms. We also measured these parameters before and 1 hour after stopping the infusion of carperitide.After stopping the infusion of carperitide, the plasma BNP level was significantly decreased by about 20% (394 ± 53.8 versus 312.8 ± 46 pg/mL, P < 0.0001) but plasma NT-proBNP did not change (1674.5 ± 282.1 versus 1777.5 ± 300.3 pg/mL, P = 0.259). The molar ratio of plasma BNP/NT-proBNP was significantly higher during carperitide infusion (0.74 ± 0.08) than those at baseline (0.63 ± 0.06) and after stopping carperitide (0.59 ± 0.07).During carperitide infusion, plasma NT-proBNP may be a more reliable marker of endogenous cardiac natriuretic peptides than plasmaBNP, which may be increased by carperitide infusion. (Int Heart J 2009; 50: 183-190) Key words: Atrial natriuretic peptide, Brain natriuretic peptide, NT-proBNP, Carperitide BRAIN or B-type natriuretic peptide (BNP) is synthesized as preproBNP mainly in the ventricular myocardium. During ventricular myocyte stretching, preproBNP is enzymatically cleaved to proBNP and released in the form of hormonally active BNP and inactive NT-proBNP. Atrial natriuretic peptide (ANP) and BNP have biologic effects such as natriuresis, diuresis, vasodilatation, and From the

show abstract

“…The blood of the CS contains information that directly or indirectly reflects cardiac metabolism and physical condition (3,4). In heart failure (HF), the information possessed by the CS may be more significant than that possessed by other anatomical locations (5,6).…”

Section: Introductionmentioning

confidence: 99%

Blood gas analysis of the coronary sinus in patients with heart failure

et al. 2015

View full text Add to dashboard Cite

Abstract. The difference in cardiac oxygen consumption between individuals with normal cardiac function and those with heart failure (HF), and the association between cardiac oxygen consumption and cardiac ejection fraction (EF) are poorly understood. By establishing a control group composed of individuals with normal cardiac function, the present study aimed to determine the difference in cardiac oxygen consumption between individuals with normal and abnormal cardiac function, as well as the association between cardiac oxygen consumption and cardiac EF. A total of 34 patients with normal cardiac function were enrolled in the control group and 44 patients with HF were enrolled in the experimental group. Blood samples from the aortic root, femoral vein and coronary sinus (CS) were collected from each patient. All the blood samples were subjected to blood gas analysis. The partial pressure of oxygen and oxygen saturation obtained from the peripheral vein and CS of patients with HF were lower than those in patients with normal cardiac function. In each patient with HF, the association between cardiac oxygen consumption and cardiac EF was analyzed using multi-linear correlation and regression analyses. Cardiac oxygen consumption negatively correlated with cardiac EF (R=-0.336, P=0.026). Furthermore, linear regression analysis suggested that cardiac EF had a significant effect on cardiac oxygen consumption (y = 82.906-0.483x, P=0.026). In conclusion, myocardial oxygen consumption is greater in individuals with HF compared to those with normal cardiac function. The cardiac EF affects myocardial oxygen consumption in patients with HF.

show abstract

Direct Comparison of Transcardiac Increase in Brain Natriuretic Peptide (BNP) and N-Terminal ProBNP and Prognosis in Patients With Chronic Heart Failure

Cited by 33 publications

References 22 publications

Dose-Dependent Prognostic Effect of Carvedilol in Patients With Chronic Heart Failure Special Reference to Ranscardiac Gradient of Norepinephrine

Dose-Dependent Prognostic Effect of Carvedilol in Patients With Chronic Heart Failure Special Reference to Ranscardiac Gradient of Norepinephrine

Plasma NT-proBNP as a More Reliable Biomarker of Endogenous Cardiac Natriuretic Peptides Than BNP During Carperitide Infusion

Blood gas analysis of the coronary sinus in patients with heart failure

Contact Info

Product

Resources

About